Synergistic Effects of Nanoscale CaO₂ Combined with PD-1 Inhibitors in the Treatment of Hepatocellular Carcinoma: A Promising Combination

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clinicians. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010–2016. Clin Mol Hepatol. 2016;22(1):7–17. doi:10.3350/cmh.2016.22.1.7
   PubMed Web of Science ®Google Scholar
• Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–2166. doi:10.1111/liv.12818
   PubMed Web of Science ®Google Scholar
• Xie DY, Ren ZG, Zhou J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452–463. doi:10.21037/hbsn-20-480
   PubMed Web of Science ®Google Scholar
• Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:v238–v255. doi:10.1093/annonc/mdy308
   Web of Science ®Google Scholar
• Lim H, Ramjeesingh R, Liu D, et al. Optimizing survival and the changing landscape of targeted therapy for intermediate and advanced hepatocellular carcinoma: a systematic review. JNCI. 2021;113(2):123–136. doi:10.1093/jnci/djaa119
   PubMedGoogle Scholar
• Sonbol MB, Riaz IB, Naqvi SAA, et al. Systemic therapy and sequencing options in advanced hepatocellular carcinoma. JAMA Oncol. 2020;6(12):e204930. doi:10.1001/jamaoncol.2020.4930
   PubMed Web of Science ®Google Scholar
• Sperandio RC, Pestana RC, Miyamura BV, et al. Hepatocellular carcinoma immunotherapy. Ann Rev Med. 2022;73(1):267–278. doi:10.1146/annurev-med-042220-021121
   PubMedGoogle Scholar
• van Doorn DJ, Takkenberg RB, Klümpen H. Immune checkpoint inhibitors in hepatocellular carcinoma: an overview. Pharmaceuticals. 2021;14(1):3. doi:10.3390/ph14010003
   Web of Science ®Google Scholar
• Park Y, Kuen D, Chung Y. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. Exp Mol Med. 2018;50(8):1–13.
   Google Scholar
• Weinmann A, Galle PR. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions. Current Oncol. 2020;27(S3):152–164. doi:10.3747/co.27.7315
   Google Scholar
• Huang AC, Postow MA, Orlowski RJ, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60–65. doi:10.1038/nature22079
   PubMed Web of Science ®Google Scholar
• Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–2139. doi:10.1016/S0140-6736(18)30789-X
   PubMed Web of Science ®Google Scholar
• Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218. doi:10.1038/s41573-018-0007-y
   PubMed Web of Science ®Google Scholar
• Demaria S, Coleman CN, Formenti SC. Radiotherapy: changing the game in immunotherapy. Trends Cancer. 2016;2(6):286–294. doi:10.1016/j.trecan.2016.05.002
   PubMed Web of Science ®Google Scholar
• Kalasekar SM, Garrido Laguna I, Evason KJ. Immune checkpoint inhibitors in combinations for hepatocellular carcinoma. Hepatology. 2021;73(6):2591–2593. doi:10.1002/hep.31706
   PubMed Web of Science ®Google Scholar
• Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Cell. 2005;7(6):513–520. doi:10.1016/j.ccr.2005.05.024
   PubMed Web of Science ®Google Scholar
• Jin M, Jin W. The updated landscape of tumor microenvironment and drug repurposing. Sig Transd Target Ther. 2020;5(1):166. doi:10.1038/s41392-020-00280-x
   PubMed Web of Science ®Google Scholar
• Wang JX, Choi SYC, Niu X, et al. Lactic acid and an acidic tumor microenvironment suppress anticancer immunity. Int J Mol Sci. 2020;21(21):8363. doi:10.3390/ijms21218363
   PubMed Web of Science ®Google Scholar
• Heintzman DR, Fisher EL, Rathmell JC. Microenvironmental influences on T cell immunity in cancer and inflammation. Cell Mol Immunol. 2022;19(3):316–326. doi:10.1038/s41423-021-00833-2
   PubMed Web of Science ®Google Scholar
• Vito A, El-Sayes N, Mossman K. Hypoxia-driven immune escape in the tumor microenvironment. Cells. 2020;9(4):992. doi:10.3390/cells9040992
   PubMed Web of Science ®Google Scholar
• Damgaci S, Ibrahim-Hashim A, Enriquez-Navas PM, et al. Hypoxia and acidosis: immune suppressors and therapeutic targets. Immunology. 2018;154(3):354–362. doi:10.1111/imm.12917
   PubMed Web of Science ®Google Scholar
• Hatfield SM, Kjaergaard J, Lukashev D, et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Trans Med. 2015;7(277). doi:10.1126/scitranslmed.aaa1260
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhao Y, Shen J, et al. Nanoenabled modulation of acidic tumor microenvironment reverses anergy of infiltrating T cells and potentiates Anti-PD-1 therapy. Nano Lett. 2019;19(5):2774–2783. doi:10.1021/acs.nanolett.8b04296
   PubMed Web of Science ®Google Scholar
• He J, Fu L, Qi C, et al. Metal peroxides for cancer treatment. Bioact Mater. 2021;6(9):2698–2710. doi:10.1016/j.bioactmat.2021.01.026
   PubMed Web of Science ®Google Scholar
• Tang Z, Liu Y, He M, et al. Chemodynamic therapy: tumour microenvironment-mediated Fenton and Fenton-like reactions. Angew Chem Int Ed Engl. 2019;58(4):946–956. doi:10.1002/anie.201805664
   PubMed Web of Science ®Google Scholar
• Kong H, Chu Q, Fang C, et al. Cu–ferrocene‐functionalized CaO2Cu–ferrocene-functionalized CaO 2 nanoparticles to enable tumor‐specific synergistic therapy with GSH depletion and calcium overload. Adv Sci. 2021;8(14):e2100241. doi:10.1002/advs.202100241
   Web of Science ®Google Scholar
• Wang X, Li C, Jin H, et al. Mutual promotion of oxidative stress amplification and calcium overload by degradable spatially selective self-cascade catalyst for synergistic tumor therapy. Chem Eng J. 2022;432:134438. doi:10.1016/j.cej.2021.134438
   Web of Science ®Google Scholar
• Wang Y, He X, Zhou C, et al. Nanoscale CaO2 materials for synergistic transarterial chemoembolization in a VX2 orthotopic rabbit liver cancer model. Acta Biomater. 2022;154:536–548. doi:10.1016/j.actbio.2022.09.074
   PubMed Web of Science ®Google Scholar
• Huang S, Li T, Chen Y, et al. Microwave ablation combined with anti-PD-1 therapy enhances systemic antitumor immunity in a multitumor murine model of Hepa1-6. Int J Hyperthermia. 2022;39(1):278–286. doi:10.1080/02656736.2022.2032406
   PubMed Web of Science ®Google Scholar
• Li L, Liu Y, Li H, et al. Rational design of temperature-sensitive blood-vessel-embolic nanogels for improving hypoxic tumor microenvironment after transcatheter arterial embolization. Theranostics. 2018;8(22):6291–6306. doi:10.7150/thno.28845
   PubMed Web of Science ®Google Scholar
• Bao X, Shen N, Lou Y, et al. Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101. Theranostics. 2021;11(12):5955–5969. doi:10.7150/thno.58164
   PubMed Web of Science ®Google Scholar
• Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727–742.
   PubMed Web of Science ®Google Scholar
• Singleton DC, Macann A, Wilson WR. Therapeutic targeting of the hypoxic tumour microenvironment. Nat Rev Clin Oncol. 2021;18(12):751–772. doi:10.1038/s41571-021-00539-4
   PubMed Web of Science ®Google Scholar
• Gong F, Xu J, Liu B, et al. Nanoscale CaH2 materials for synergistic hydrogen-immune cancer therapy. Chem. 2022;8(1):268–286. doi:10.1016/j.chempr.2021.11.020
   Web of Science ®Google Scholar
• Zhang M, Song R, Liu Y, et al. Calcium-overload-mediated tumor therapy by calcium peroxide nanoparticles. Chem. 2019;5(8):2171–2182. doi:10.1016/j.chempr.2019.06.003
   Web of Science ®Google Scholar